bluuebunny/crossref_metadata_2025_split huggingface dataset:
Sinus pilonidalis—elastic ligature as an optimal outpatient treatment
Authors: Danihel Ľudovít , Černý Marián , Rajčok Matúš , Mosná Kristína , Bou Ezzeddine Jihad , Dropco Ivor , Schnorrer Milan 
Published: December 2023

Abstract
Background
The incidence of pilonidal sinus shows a steadily rising tendency, especially in the patient age group of up to 40 years. Treatment of this condition is often protracted involving lengthy sick leave and an increased risk of recurrence. The optimal treatment of pilonidal sinus remains open to debate, but it should focus on decreasing the length of hospitalization, promoting a rapid return to daily life, maintaining low pain levels, and keeping costs at a minimum.

Materials and methods
In our study conducted between 2017 and 2021, we focused on treatment of pilonidal sinus. We performed 50 elastic ligature procedures with a median observation time of 30 months. The patients were divided into three groups according to the characteristics of pilonidal sinus: (1) acute primary abscess; (2) acute recurrent abscess; and (3) chronic fistula.

Results
Out of a total of 50 patients with a subsequent 30-month follow-up, we observed complete recovery in 47 patients and recurrence in three patients. Return to work was possible immediately after the operation, with an average total treatment time of 1 month for complete healing of the defect.

Conclusion
The current results suggest that the technique of elastic ligature is a desirable solution for pilonidal sinus, because of the initial low costs, no need for hospitalization, and good patient tolerance.
Dose–response effects on HbA1c and bodyweight reduction of survodutide, a dual glucagon/GLP-1 receptor agonist, compared with placebo and open-label semaglutide in people with type 2 diabetes: a randomised clinical trial
Authors: Blüher Matthias , Rosenstock Julio , Hoefler Josef , Manuel Raymond , Hennige Anita M. 
Published: December 2023

Abstract
Aims/hypothesis
The aim of this study was to assess the dose–response effects of the subcutaneous glucagon receptor/glucagon-like peptide-1 receptor dual agonist survodutide (BI 456906) on HbA1c levels and bodyweight reduction.

Methods
This Phase II, multicentre, randomised, double-blind, parallel-group, placebo-controlled study, conducted in clinical research centres, assessed survodutide in participants aged 18–75 years with type 2 diabetes, an HbA1c level of 53–86 mmol/mol (7.0–10.0%) and a BMI of 25–50 kg/m2 on a background of metformin therapy. Participants were randomised via interactive response technology to receive survodutide (up to 0.3, 0.9, 1.8 or 2.7 mg once weekly [qw; dose group (DG) 1–4, respectively] or 1.2 or 1.8 mg twice weekly [DG 5 and 6, respectively]), placebo or semaglutide (up to 1.0 mg qw). Participants and all those involved in the trial conduct/analysis were blinded; the semaglutide arm was open-label. The primary endpoint was absolute change from baseline in HbA1c after 16 weeks’ treatment. The key secondary endpoint was relative change from baseline in bodyweight after 16 weeks’ treatment.

Results
A total of 413 participants were randomised (DG1, n=50; DG2, n=50; DG3, n=52; DG4, n=50; DG5, n=51; DG6, n=50; semaglutide, n=50; placebo, n=60). The full analysis set comprised 411 treated participants (DG6, n=49; placebo, n=59). Adjusted mean (95% CI) HbA1c decreased from baseline (mean ± SD 64.7±9.2 mmol/mol [8.07±0.84%] after 16 weeks’ treatment: DG1 (n=41), −9.92 mmol/mol (−12.27, −7.56; −0.91% [−1.12, −0.69]); DG2 (n=46), −15.95 mmol/mol (−18.27, −13.63; −1.46% [−1.67, −1.25]); DG3 (n=36), −18.72 mmol/mol (−21.15, −16.29; −1.71% [−1.94, −1.49]); DG4 (n=33), −17.01 mmol/mol (−19.59, −14.43; −1.56% [−1.79, −1.32]); DG5 (n=44), −17.84 mmol/mol (−20.18, −15.51; −1.63% [−1.85, −1.42]); DG6 (n=36), −18.38 mmol/mol (−20.90, −15.87; −1.68% [−1.91, −1.45]). The mean reduction in HbA1c was similar with low-dose survodutide (DG2: −15.95 mmol/mol [−1.46%]; n=46) and semaglutide (−16.07 mmol/mol [−1.47%]; n=45). Mean (95% CI) bodyweight decreased dose-dependently up to −8.7% (−10.1, −7.3; DG6, n=37); survodutide ≥1.8 mg qw produced greater bodyweight reductions than semaglutide (−5.3% [−6.6, −4.1]; n=45). Adverse events (AEs) were reported for 77.8% of survodutide-treated participants (mainly gastrointestinal), 52.5% receiving placebo and 52.0% receiving semaglutide.

Conclusions/interpretation
Survodutide reduced HbA1c levels and bodyweight after 16 weeks’ treatment in participants with type 2 diabetes. Dose-related gastrointestinal AEs could be mitigated with slower dose escalations.

Trial registration
ClinicalTrials.gov NCT04153929 and EudraCT 2019-002390-60.

Funding
Boehringer Ingelheim Pharma GmbH & Co. KG, Ingelheim, Germany.

Graphical Abstract
Hyperglycaemia, diabetes and risk of fragility fractures: observational and Mendelian randomisation studies
Authors: Emanuelsson Frida , Afzal Shoaib , Jørgensen Niklas R. , Nordestgaard Børge G. , Benn Marianne 
Published: December 2023

Abstract
Aims/hypothesis
Fragility fractures may be a complication of diabetes, partly caused by chronic hyperglycaemia. We hypothesised that: (1) individuals with hyperglycaemia and diabetes have increased risk of fragility fracture; (2) hyperglycaemia is causally associated with increased risk of fragility fracture; and (3) diabetes and fragility fracture jointly associate with the highest risk of all-cause mortality.

Methods
In total, 117,054 individuals from the Copenhagen City Heart Study and the Copenhagen General Population Study (the Copenhagen studies) and 390,374 individuals from UK Biobank were included for observational and one-sample Mendelian randomisation (MR) analyses. Fragility fractures were defined as fractures at the hip, spine and arm (humerus/wrist), collected from national health registries. Summary data for fasting glucose and HbA1c concentrations from 196,743 individuals in the Meta-Analyses of Glucose and Insulin-related traits Consortium (MAGIC) were combined with data on fragility fractures from the Copenhagen studies in two-sample MR analyses.

Results
Higher fasting and non-fasting glucose and HbA1c concentrations were associated with higher risk of any fragility fracture (p<0.001). Individuals with vs without diabetes had HRs for fragility fracture of 1.50 (95% CI 1.19, 1.88) in type 1 diabetes and 1.22 (1.13, 1.32) in type 2 diabetes. One-sample MR supported a causal association between high non-fasting glucose concentrations and increased risk of arm fracture in the Copenhagen studies and UK Biobank combined (RR 1.41 [1.11, 1.79], p=0.004), with similar results for fasting glucose and HbA1c in two-sample MR analyses (ORs 1.50 [1.03, 2.18], p=0.03; and 2.79 [1.12, 6.93], p=0.03, respectively). The corresponding MR estimates for any fragility fracture were 1.18 (1.00, 1.41), p=0.06; 1.36 (0.89, 2.09), p=0.15; and 2.47 (0.95, 6.43), p=0.06, respectively. At age 80 years, cumulative death was 27% in individuals with fragility fracture only, 54% in those with diabetes only, 67% in individuals with both conditions and 17% in those with neither.

Conclusions/interpretation
Hyperglycaemia and diabetes are risk factors for fragility fracture and one- and two-sample MR analyses supported a causal effect of hyperglycaemia on arm fractures. Diabetes and previous fragility fracture jointly conferred the highest risk of death in the general population.

Graphical Abstract
Improvement of electrical and mechanical properties of laser welded lap joints via dimensional optimization
Authors: Horváth Gábor , Körmöczi Andor , Szörényi Tamás , Geretovszky Zsolt 
Published: December 2023

AbstractWith the proliferation of electric drivetrains, the development and optimization of joining techniques for the fabrication of battery packs became a prime manufacturing topic. Decreasing the electrical resistance and increasing the mechanical strength of the welds at the individual cell level are of great importance not only for productivity and efficiency but also for safety and sustainability purposes. Lasers offer an advanced, highly automatable solution for battery cell joining. Usually, the optimization focuses on the laser parameters or the scanning speed. However, the most widespread battery welding geometry, the so-called lap geometry, allows alternative possibilities for joint property optimization. The novelty of our approach is that we focus on systematic experimental investigation of the effects of dimensional parameters and the layout of the weld pattern. Systematic experiments reveal that the shape and size of the weld area have substantial effect on the properties of the laser welded joint. Our results prove that a rather substantial gain can be achieved in both the electrical and mechanical properties when the weld consists of at least two parallel bead segments. We also show that it is beneficial by both means if the segments have the greatest individual length and placed apart at the maximum feasible distance. The orientation of the straight segments affects the mechanical and electrical behavior differently: strongest welds consist of weld segments oriented in parallel, while the smallest resistance can be achieved using segments oriented perpendicular to the direction of current flow, respectively.
Culturomics reveals a hidden world of vaginal microbiota with the isolation of 206 bacteria from a single vaginal sample
Authors: Abou Chacra Linda , Benatmane Amel , Iwaza Rim , Ly Claudia , Alibar Stéphane , Armstrong Nicholas , Mediannikov Oleg , Bretelle Florence , Fenollar Florence 
Published: December 2023

AbstractThe composition of the vaginal microbiota is known to be influenced by various factors and to be associated with several disorders affecting women’s health. Although metagenomics is currently a widely used method for studying the human microbiota, it has certain limitations, such as a lack of information on bacterial viability. It is therefore important to use culture-based methods such as culturomics. Here, we used 35 different culture conditions to comprehensively characterize the vaginal bacterial diversity of a single woman's flora. A total of 206 bacterial species, belonging to six phyla (for a little more than half to Firmicutes, followed mainly by Actinobacteria, Bacteroidetes, and Proteobacteria) and 45 families, and 2 fungal species were cultivated. While several species of lactobacilli have been isolated, a wide variety of other bacteria were also separated, including 65 never reported before in vaginal flora, including a new bacterial species, Porphyromonas vaginalis sp. nov. Extensive culture-based methods are essential to establish a comprehensive, evidence-based repertoire of bacterial viability. If combined with molecular methods, they can provide a much more thorough understanding of the vaginal microbiota and fulfil the unknown part of metagenomic studies.
The crown-of-thorns seastar species complex: knowledge on the biology and ecology of five corallivorous Acanthaster species
Authors: Uthicke Sven , Pratchett Morgan S. , Bronstein Omri , Alvarado Juan José , Wörheide Gert 
Published: December 2023

AbstractCoral-eating crown-of-thorns seastars (CoTS, Acanthaster spp.) are major contributors to the coral reef crises across the Indo-Pacific region. Until recently, CoTS throughout the Indo-Pacific were regarded to be a single species, Acanthaster planci. However, genetic and morphological analyses demonstrated that there are at least four distinct species: Acanthaster benziei in the Red Sea, Acanthaster mauritiensis and A. planci in the Indian Ocean, and Acanthaster cf. solaris in the western Pacific. Acanthaster cf. ellisii in the eastern Pacific needs more taxonomic attention. Here, we review the biological knowledge for each species adapting a pragmatic geographical species definition and using a systematic literature review complemented with more focused searches for individual species. The vast majority of CoTS research (88%) was conducted on A. cf. solaris, with much of this research undertaken on the Great Barrier Reef or in Japan. Many studies of A. cf. solaris are focused on monitoring or documenting incidences of outbreaks, though there is a solid base of knowledge on larval, juvenile and adult ecology derived from field and laboratory experiments. By contrast, most of the published studies on the four remaining species simply document cases of population outbreaks. The major taxonomic bias in CoTS research constitutes a significant limitation for understanding and managing these species for two reasons. First, even for A. cf. solaris, which is the most studied species, limited fundamental knowledge of their biology and ecology constrains understanding of the drivers of outbreaks and hinders corresponding management actions for prevention and control of these events. Second, understanding and management of other species are predicated on the assumption that all CoTS species have similar biology and behaviour, an unsatisfying assumption for ecosystem management.
Enhanced Fat Graft Viability and Remodeling Using a Helium-based Radiofrequency Device to Prepare the Recipient Site
Authors: Ruff Paul G. , Sterodimas Aris 
Published: December 2023

Abstract
Background
Improvements to autologous fat grafting for soft tissue augmentation are needed to overcome the unpredictable volume retention. Approaches such as fat harvesting and processing, injection technique, preparation of the recipient site, and supplemental biologics are topics of ongoing research. Here, an energy-based device was investigated as a stimulatory tool for recipient site preparation for improving fat graft retention.

Objective
The objective was to measure the stimulatory responses in fat grafts after 4 weeks when using a helium-based radiofrequency device to pretreat the recipient tissue.

Methods
Using an autologous fat grafting mouse model, the inguinal fat pad was grafted in a small cranial pocket after either a saline injection alone (control) or a saline injection followed by pretreatment (treated). The fat pad was resected after 4 weeks, sectioned and stained with immunofluorescence markers to investigate tissue remodeling.

Results
Pretreatment resulted in higher viability of adipocytes, a higher concentration of viable ASCs in areas of adipose tissue regeneration, and localized macrophages in the areas of regeneration when compared to the control. There was no observable difference in vascularity or angiogenesis. The staining for ASCs was higher in the pretreated group in comparison with the control group (5.0% vs. 3.3%, p=0.36) when using a pixel classifier in QuPath in the viable adipose tissue regions.

Conclusions
The use of a helium-based radiofrequency device as a pretreatment tool appears to increase the viability of the adipose tissue likely due to higher concentration of ASCs. The apparent increase in viable ASCs may be due to enhanced proliferation or paracrine recruitment of these cells in response to the helium-based radiofrequency treatment.

No Level Assigned
This journal requires that authors assign a level of evidence to each submission to which Evidence-Based Medicine rankings are applicable. This excludes Review Articles, Book Reviews, and manuscripts that concern Basic Science, Animal Studies, Cadaver Studies, and Experimental Studies. For a full description of these Evidence-Based Medicine ratings, please refer to the Table of Contents or the online Instructions to Authors www.springer.com/00266.
Bullet List of Important Points:

Pretreatment of the fat graft recipient site increases the viability of the adipose tissue after 4 weeks in comparison with the control grafts.

The increased viability is likely due to the observed increase in adipose-derived stem cells in the pretreated group.

Pretreatment enhanced the adipose tissue remodeling as colocalization of adipose-derived stem cells and macrophages showed an active remodeling, whereas the control group exhibited more necrotic and fibrotic tissue.
Effectiveness of tixagevimab/cilgavimab in patients with hematological malignancies as a pre-exposure prophylaxis to prevent severe COVID-19: a Czech retrospective multicenter study
Authors: Demel Ivo , Skopal David , Šafránková Eliška , Rozsívalová Petra , Jindra Pavel , Šrámek Jiří , Turková Adéla , Vydra Jan , Labská Klára , Vedrová Jana , Čerňan Martin , Szotkowski Tomáš , Móciková Heidi , Hynková Lenka , Šušol Ondrej , Kováčová Ingrid , Belada David , Hájek Roman 
Published: December 2023

AbstractDespite lower virulence, the omicron variant of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that causes coronavirus disease 2019 (COVID-19) still poses a relevant threat for immunocompromised patients. A retrospective multicentric study was conducted to evaluate the efficacy of pre-exposure prophylaxis with tixagevimab/cilgavimab (Evusheld) with a 6-month follow-up for preventing severe COVID-19 in adult patients with hematology malignancy. Among the 606 patients in the cohort, 96 (16%) contracted COVID-19 with a median of 98.5 days after Evusheld administration. A total of 75% of patients had asymptomatic or mild severity of COVID-19, while just 25% of patients with SARS-CoV-2 positivity had to be hospitalized. Two patients (2%) died directly, and one patient (1%) in association with COVID-19. Eight patients (1.3%) of every cohort experienced adverse events related to Evusheld, mostly grade 1 and of reversible character. It was found that complete vaccination status or positive seroconversion was not associated with lower risk of COVID-19 infection. Previous treatment with an anti-CD20 monoclonal antibody was associated with higher rates of COVID-19, while previous treatment with anti-CD38 monoclonal antibody was not, as was the case for recipients of hematopoietic stem cell transplantation or CAR-T cell therapy. Presence of other comorbidities was not associated with more severe COVID-19. The results support the growing evidence for Evusheld’s efficacy against severe COVID-19 in patients with hematology malignancies.
Safe use of contrast media in myasthenia gravis: systematic review and updated European Society of Urogenital Radiology Contrast Media Safety Committee guidelines
Authors: Geenen Remy W. F. , Roditi Giles , Bellin Marie-France , Bertolotto Michele , Brismar Torkel , Correas Jean-Michel , Dekkers Ilona A. , Heinz-Peer Gertraud , Mahnken Andreas H. , van der Molen Aart J. , Quattrocchi Carlo C. , Radbuch Alexander , Reimer Peter , Sebastià Maria , Stacul Fulvio , Romanini Laura , Clément Olivier ,   on behalf of the Contrast Media Safety Committee
Published: December 2023

Abstract
Objectives
It is uncertain whether modern iodine-based or gadolinium-based contrast media (CM) administration can lead to increased symptoms in patients with myasthenia gravis.

Methods
A systematic search in Medline was conducted for studies describing the symptomatology of myasthenia gravis patients before and after receiving intravenous (IV) CM and having a matched control group of myasthenia gravis patients who did not receive IV CM.

Results
Three retrospective studies were selected with a total of 374 myasthenia gravis patients who received iodine-based CM and a total of 313 myasthenia gravis patients who underwent unenhanced CT and served as controls. Pooling of the data from the three retrospective studies showed that in 23 of 374 patients, increased symptoms after iodine-based CM administration were described (6.1%). Increased symptomatology also occurred in 11 of 313 patients after unenhanced CT (3.5%). When looking more deeply into the data of the three studies, conflicting results were found, as two articles did not find any relationship between CM and myasthenia gravis symptoms. The remaining study only found a significant increase in symptomatology within 1 day after CT scanning: seven patients (6.3%) in the contrast-enhanced CT group and one patient (0.6%) in the unenhanced CT group (p = 0.01).

Conclusions
There is limited evidence on the relationship between CM and myasthenia gravis symptoms. In the vast majority of myasthenia gravis patients, CM are safe. Probably, in less than 5% of the patients, iodine-based CM administration may lead to increased severity of the symptoms within the first 24 h after administration.

Clinical relevance statement
Be aware that intravenous administration of iodine-based contrast media can lead to an increase of symptoms in patients with myasthenia gravis within the first 24 h. This can probably happen in less than 5% of the patients.

Key Points
• It is unclear whether modern contrast media can lead to increased symptoms in myasthenia gravis patients after intravenous administration.
• There seems to be a small risk of increased myasthenia gravis symptoms within 24 h after intravenous administration of iodine-based contrast media, probably in less than 5% of the administrations.
• Gadolinium-based contrast media are safe for patients with myasthenia gravis.
LD block disorder-specific pleiotropic roles of novel CRHR1 in type 2 diabetes and depression disorder comorbidity
Authors: del Bosque-Plata Laura , Amin Mutaz , González-Ramírez Ricardo , Wu Rongling , Postolache Teodor T. , Vergare Michael , Gordon Derek , Gragnoli Claudia 
Published: December 2023

AbstractMajor depressive disorder (MDD) and type 2 diabetes (T2D) are complex disorders whose comorbidity can be due to hypercortisolism and may be explained by dysfunction of the corticotropin-releasing hormone receptor 1 (CRHR1) and cortisol feedback within the hypothalamic–pituitary–adrenal axis (HPA axis). To investigate the role of the CRHR1 gene in familial T2D, MDD, and MDD-T2D comorbidity, we tested 152 CRHR1 single-nucleotide-polymorphisms (SNPs), via 2-point parametric linkage and linkage disequilibrium (LD; i.e., association) analyses using 4 models, in 212 peninsular families with T2D and MDD. We detected linkage/LD/association to/with MDD and T2D with 122 (116 novel) SNPs. MDD and T2D had 4 and 3 disorder-specific novel risk LD blocks, respectively, whose risk variants reciprocally confirm one another. Comorbidity was conferred by 3 novel independent SNPs. In silico analyses reported novel functional changes, including the binding site of glucocorticoid receptor-alpha [GR-α] on CRHR1 for transcription regulation. This is the first report of CRHR1 pleiotropic linkage/LD/association with peninsular familial MDD and T2D. CRHR1 contribution to MDD is stronger than to T2D and may antecede T2D onset. Our findings suggest a new molecular-based clinical entity of MDD-T2D and should be replicated in other ethnic groups.
Increasing age of multiple sclerosis onset from 1920 to 2022: a population-based study
Authors: Habbestad A. , Willumsen J. S. , Aarseth J. H. , Grytten N. , Midgard R. , Wergeland S. , Myhr K. M. , Torkildsen Ø. 
Published: December 2023

Abstract
Objective
To study the age at onset of relapsing–remitting multiple sclerosis (RRMS) during the past century.

Methods
This is a population-based cohort study of persons diagnosed with RRMS in Hordaland, Møre, and Romsdal counties, Western Norway, from 1920 to 2022. Individual patient data were available and assessed from previously conducted prevalence and incidence studies in addition to hospital records up until October 31, 2022. Participants were categorized according to onset period and analyzed for temporal trends in age at onset, time from onset to diagnosis, and distribution of onset over time.

Results
We identified 3364 persons with confirmed RRMS. The mean age at onset significantly increased (p < 0.001) throughout the study period, despite a decrease in time from symptom onset to diagnosis (p < 0.001). The proportion of persons with MS onset after 50 years of age increased from 2.6% before 1970 to 11.9% after 2010. We also found a trend toward a bimodal distribution of age at onset that peaked at around 30 years and 40–45 years of age in the latest period.

Conclusion
Age at onset of MS significantly increased throughout the study period. This was mainly due to an increasing number of persons with MS, predominantly female, experiencing onset after 40–45 years of age. This bimodal distribution could indicate different susceptibility periods of MS or changes in exposure to risk factors during the observation period.